Sigyn Therapeutics, Inc. has released details about CardioDialysis, a medical device developed to reduce the incidence of major adverse cardiovascular events. Cardiovascular disease remains the leading cause of death worldwide, with current therapies like LDL-C reducing statins lowering MACE by approximately 25%. In contrast, lipoprotein apheresis devices have demonstrated the ability to reduce MACE by 75-95%, according to the American Heart Association, yet their adoption has been limited by complex designs and infrastructure constraints.
CardioDialysis represents a significant advancement in subtractive medicine as the first technology to fully integrate plasma separation and therapeutic adsorption within a single device. This integration allows deployment on existing dialysis machines already located in more than 5,000 hospitals and 7,500 dialysis clinics across the United States. The device enables continuous broad-spectrum clearance of both inflammatory and pathogenic molecules from the entire bloodstream, addressing a broader range of cardiovascular disease targets than previous technologies.
The limitations of current apheresis technologies are exemplified by the FDA-approved Kaneka LIPOSORBER procedure, which requires multiple components including separation columns, cartridges, custom tubing sets, pumps, and various fluid bags. This complexity restricts access to fewer than 60 specialized apheresis centers in the United States. CardioDialysis overcomes these limitations with a fully integrated single-component design that processes blood more efficiently without requiring replacement fluids, additional pumps, or auxiliary components.
Given that 15-20% of major adverse cardiovascular events result in death, the successful clinical advancement of CardioDialysis could save thousands of lives each year. The technology aims to reduce circulating inflammatory mediators that fuel cardiovascular disease progression while simultaneously lowering levels of cholesterol-transporting lipoproteins that contribute to heart attacks, strokes, and other MACE. This dual approach overcomes the inherent limitations of single-target drugs currently available.
Sigyn Therapeutics' development pipeline includes additional technologies such as ImmunePrep to optimize immunotherapeutic antibody delivery for cancer treatment, ChemoPrep to enhance targeted chemotherapy delivery, and ChemoPure to reduce chemotherapy toxicity. More information about the company's technologies can be found at www.SigynTherapeutics.com. The original press release detailing this announcement is available through www.newmediawire.com.
